NAD+ (IV and Injectable)
NAD+ given directly by infusion or injection, as sold in wellness and longevity clinics — distinct from the oral precursors NMN and NR. The only published human pharmacokinetic study found that infused NAD+ disappears from plasma for the first two hours, broken down before it reaches cells, and no randomised trial has tested it against any clinical endpoint.
NAD+ drips are sold in wellness clinics as an energy and anti-aging treatment. The problem is that NAD+ is a large molecule that cells mostly cannot take in whole — enzymes in your blood chop it up first, and the one published human study found no rise in blood NAD+ for the first two hours of a six-hour infusion. It is not FDA-approved, no trial has tested whether it does anything you would notice, and the one country that does approve an NAD+ injection uses doses about a hundred times smaller than a typical clinic drip.
What is NAD+ (IV and Injectable)?
This page is about NAD+ itself, given parenterally — the intravenous drips and subcutaneous or intramuscular injections sold by wellness clinics, longevity practices and increasingly by direct-to-consumer peptide vendors. That is a different product from the oral precursors covered on the NAD+ precursors page, and the distinction is the whole point: NMN and NR are small molecules designed to be absorbed and then converted into NAD+ inside the cell, whereas IV NAD+ delivers the finished coenzyme into the bloodstream and assumes it will get where it needs to go. A note on scope first. NAD+ is not a peptide. It is a dinucleotide — two nucleotides joined by a phosphate bridge, with a molecular weight of about 663 daltons — and it appears in this directory for the same reason NMN and NR do: the longevity and peptide-clinic world sells them side by side, often in the same visit, and people looking for an honest assessment expect to find one here. Calling it a peptide would be wrong; leaving it out would be unhelpful. NAD+ does everything the marketing says it does, inside the cell. It is the electron carrier that makes oxidative metabolism possible, the substrate sirtuins consume when they deacetylate their targets, the substrate PARP enzymes consume during DNA repair, and the substrate CD38 consumes in immune signalling. Cellular NAD+ declines with age. None of that is in dispute. What is in dispute — or rather, what the marketing simply does not address — is whether putting NAD+ into a vein raises it inside cells. Extracellular NAD+ encounters a set of ectoenzymes before it encounters a cell membrane: CD38 and other NAD+ glycohydrolases cleave it, pyrophosphatases split it, and the resulting fragments are what cells actually import, through transporters built for precursors rather than for the intact dinucleotide. The one published human study of an NAD+ infusion found exactly that signature — no measurable rise in plasma NAD+ or its metabolites for the first two hours of a six-hour infusion, and a downstream metabolite profile the authors described as consistent with glycohydrolase and pyrophosphatase activity. As of November 2026 there is no FDA-approved NAD+ injection in the United States, no completed randomised trial of IV NAD+ against a clinical endpoint anywhere, and no published pharmacokinetic study beyond that single 2019 pilot. There is one country where an NAD+ injection is an approved prescription drug — China — and the approved dose there is roughly two orders of magnitude below what Western clinics infuse.
What NAD+ (IV and Injectable) Is Investigated For
Every use on this list is promoted commercially and none is supported by a randomised controlled trial of intravenous NAD+ against a clinical endpoint. That is not a rhetorical framing; it is the state of the literature as of November 2026. The foundational claim — that IV delivery raises cellular NAD+ better than swallowing a precursor — is the one most worth examining, because everything else depends on it. The only published human pharmacokinetic study infused roughly 700 mg of NAD+ over six hours and found no change in plasma NAD+, nicotinamide, methylnicotinamide, ADP-ribose or NMN until after the two-hour mark. The authors' conclusion was that NAD+ is rapidly and completely removed from plasma for at least the first two hours, with a metabolite profile consistent with enzymatic cleavage rather than intact uptake. A separate cell-biology study found that prolonged exposure to extracellular NAD+ produces an initial intracellular rise followed by a return to baseline, driven by a sirtuin-1-dependent downregulation of the very transporters and kinases that import NAD+ breakdown products. Cells appear to actively defend their NAD+ set point against an external flood. The addiction-recovery application deserves specific mention because it is the most aggressively marketed and the thinnest. Searching PubMed for intravenous NAD+ in addiction or withdrawal returns nothing. There is no registered randomised trial, no published case series with controls, and no mechanism specific to substance withdrawal that has been tested in people. Clinics offering multi-day NAD+ infusion protocols for opioid or alcohol withdrawal are selling an unstudied intervention to a population in an unusually vulnerable state. The one indication with any regulatory standing is the Chinese one, and it is not what Western clinics are selling. Coenzyme I for Injection is approved in China as an adjunctive treatment in leukopenia and in coronary heart disease and myocarditis, at a 5 mg strength. That is a hospital adjunct at a milligram dose, not a wellness drip.
History & Discovery
NAD+ was identified in 1906 by Arthur Harden and William Young as a heat-stable fraction of yeast extract required for fermentation, which they called cozymase. Hans von Euler-Chelpin determined its structure and shared the 1929 Nobel Prize in Chemistry for the work; Otto Warburg later established its role in hydride transfer. The name Coenzyme I, still used in the Chinese pharmacopoeia and in the Chinese product name, is a direct inheritance from that era. The therapeutic use of NAD+ by injection also has a longer history than the current wellness market suggests, and its origins are specific. Canadian psychiatrists Abram Hoffer and Humphry Osmond worked with high-dose niacin and niacinamide in schizophrenia and alcoholism from the 1950s, a programme that became the basis of what Linus Pauling later named orthomolecular medicine. Intravenous NAD+ for addiction, promoted through the late twentieth century and into the present by a series of private clinics, traces to that lineage rather than to any controlled trial, and no randomised trial of the practice has been published in the seventy years since. The modern surge is academic in origin and precursor-based in substance. Work from the 2000s onward — Charles Brenner's identification of nicotinamide riboside as a distinct precursor in 2004, Shin-ichiro Imai's work on NAMPT and NMN, David Sinclair's laboratory on sirtuins and NAD+ decline — established that cellular NAD+ falls with age and that raising it with precursors produces measurable effects in rodents. That body of work is about NMN and NR. The wellness industry's extension of it to infused NAD+ was a commercial inference, not a scientific one, and the pharmacokinetic study that would have tested it was not published until 2019 — more than a decade after NAD+ drips were being sold. The 2019 result has not changed the market. NAD+ infusion remains one of the fastest-growing services in longevity and wellness clinics, sold alongside peptide protocols, and has more recently appeared as a self-injected subcutaneous product from research-chemical vendors. The regulatory position in the United States settled into its current shape through the 503A nomination process, where NAD and NADH sit in Category 1 — under evaluation — which is what allows compounding pharmacies to supply it while the FDA has reached no conclusion.
How It Works
NAD+ is a molecule every cell needs to turn food into energy and to run repair enzymes, and cells have less of it as you get older. The theory behind an NAD+ drip is simple: put the finished molecule into the blood and let cells take it up. The complication is that NAD+ is relatively large and the bloodstream is full of enzymes that cut it apart on contact. What reaches the cell surface is mostly fragments, and cells import fragments through transporters built for smaller building blocks — which is the same thing that happens when you swallow a precursor, only more expensively.
NAD+ is a dinucleotide of about 663 daltons that functions in two distinct ways inside the cell. As a redox cofactor it cycles between NAD+ and NADH, accepting and donating electrons in glycolysis, the citric acid cycle and oxidative phosphorylation, and this pool is recycled rather than consumed. As a substrate it is consumed and destroyed: sirtuins cleave NAD+ to transfer an acetyl group during deacetylation, PARP enzymes consume it to build poly-ADP-ribose chains during DNA repair, and CD38 hydrolyses it as part of calcium signalling. It is the second role that creates demand for synthesis, and rising CD38 expression with age is one of the better-supported explanations for why cellular NAD+ falls. The salvage pathway that maintains that pool is built around small precursors, not around intact NAD+. Nicotinamide is converted to NMN by NAMPT, and NMN is converted to NAD+ by NMNAT enzymes; nicotinamide riboside enters by being phosphorylated to NMN by NRK1 and NRK2. Every step in that chain operates on a molecule substantially smaller than NAD+ itself, and the transporters that move these species across the plasma membrane evolved for them. This is why the extracellular fate of infused NAD+ is the crux of the entire category. The outer face of the plasma membrane carries ectoenzymes that act on NAD+ directly: CD38 is an NAD+ glycohydrolase, ENPP1 and related pyrophosphatases cleave the pyrophosphate bridge to yield NMN and AMP, and CD73 dephosphorylates NMN to nicotinamide riboside. The sequence CD38, ENPP1 and CD73 constitutes a disassembly line that converts extracellular NAD+ into precursors before uptake. The strong prior from this biology is that an NAD+ infusion is, functionally, an expensive and slow precursor infusion. The human data available are consistent with that prior rather than against it. In the 2019 pilot — the only published human pharmacokinetic study of an NAD+ infusion — participants received 3 µmol per minute for six hours, about 700 mg in total, and plasma showed no change in NAD+, nicotinamide, methylnicotinamide, ADP-ribose or NMN until after two hours. Urinary excretion of methylnicotinamide and of NAD+ itself rose by six hours, while urinary nicotinamide did not. The authors drew three conclusions: that NAD+ was rapidly and completely removed from plasma for at least the first two hours, that the metabolite profile was consistent with glycohydrolase and pyrophosphatase activity, and that the excreted products included intact NAD+ and methylnicotinamide but not nicotinamide. Infused NAD+ is disassembled and partly excreted; the study did not show it entering cells intact and was not designed to. There is a further layer that the marketing never addresses: cells appear to resist being loaded. A 2021 study in the Journal of Biological Chemistry exposed several cell types to prolonged extracellular NAD+ and found intracellular NAD+ rose and then returned to control levels — a phenomenon the authors termed resetting. Radiolabelling showed this was not caused by cells expelling the dinucleotide but by reduced uptake of its cleavage products, because the exposure suppressed expression of CD73, the NMN transporter SLC12A8 and nicotinamide riboside kinase. Silencing sirtuin 1 prevented both the transcriptional suppression and the resetting, identifying a sirtuin-1-mediated homeostatic response that defends the intracellular NAD+ set point against external excess. If that mechanism operates in human tissue during repeated infusions, the ceiling on what any NAD+ delivery strategy can achieve is set by the cell, not by the dose in the bag.
Evidence Snapshot
Human Clinical Evidence
One published pharmacokinetic pilot and no efficacy trials. The 2019 study in Frontiers in Aging Neuroscience remains the only published human work on the fate of directly infused NAD+: a six-hour intravenous infusion at 3 µmol per minute, roughly 700 mg total, with serial plasma and urine metabolomics. It found no change in plasma NAD+ or its measured metabolites for the first two hours, increased urinary excretion of methylnicotinamide and NAD+ at six hours, and no significant rise in urinary nicotinamide. No randomised controlled trial has tested intravenous NAD+ against placebo for fatigue, cognition, addiction, healthspan or any other clinical endpoint. NCT06382688, a 53-participant randomised comparison of intravenous NAD+, intravenous nicotinamide riboside, oral nicotinamide riboside and saline with total NAD by dried blood spot as an outcome, completed data collection in March 2024 and has posted no results, with its registry status listed as unknown since April 2024. The only interventional trial of an NAD+ injection with a disease endpoint is NCT06558253, a 12-participant Phase 1 study at a Chinese hospital giving Coenzyme I for Injection for 21 consecutive days to support haematopoietic recovery after cord blood transplantation, with adverse events as the primary outcome and estimated primary completion in April 2026.
Animal / Preclinical
Weaker than the oral precursor literature, and that asymmetry is itself informative. The influential rodent work underpinning the NAD+ field — mitochondrial function, muscle performance, metabolic and healthspan effects — used NMN or NR, administered orally or by injection, rather than NAD+ itself. Studies that do administer NAD+ directly are generally cell-based, and the most relevant of them is the resetting work showing that prolonged extracellular NAD+ exposure triggers a sirtuin-1-dependent suppression of the uptake machinery. There is no animal study demonstrating that intravenous NAD+ raises tissue NAD+ more effectively than an equivalent precursor dose, which is the experiment the commercial claim requires and which would be inexpensive to run.
Mechanistic Rationale
The intracellular biology is solid and the delivery premise is not. That NAD+ is essential, that it is consumed by sirtuins, PARPs and CD38, and that cellular levels fall with age are all well established. The step the category depends on — that an intact dinucleotide infused into a vein reaches the intracellular compartment where that biology happens — runs against the known arrangement of ectoenzymes on the cell surface, against the substrate preferences of the salvage pathway, against the only human pharmacokinetic data available, and against a documented homeostatic mechanism that actively resists extracellular loading. A strong mechanism for why NAD+ matters is not a mechanism for why infusing it works, and the two are persistently conflated in how this therapy is sold.
Research Gaps & Open Questions
What the current literature has not yet settled about NAD+ (IV and Injectable):
- 01Whether infused NAD+ raises NAD+ inside any human tissue. This has never been measured, and it is the claim the entire category rests on.
- 02Whether intravenous NAD+ outperforms an oral precursor on any outcome. NCT06382688 was designed to address a version of this question, completed data collection in March 2024, and has never posted results.
- 03Any randomised comparison against placebo on a clinical endpoint — fatigue, cognition, exercise capacity, anything. None exists.
- 04Dose-response. No dose-ranging study has been published at any dose by any route, so the hundreds-of-milligram to gram-scale infusions in clinical practice have no empirical basis.
- 05Pharmacokinetics of subcutaneous and intramuscular NAD+, which are sold commercially with no published human data whatsoever.
- 06Whether the sirtuin-1-dependent resetting observed in cells occurs in human tissue during repeated infusions, which would cap what any delivery strategy could achieve.
- 07A structured characterisation of infusion-rate reactions — frequency, mechanism, dose relationship — which are universally described in practice and absent from the literature.
- 08Any controlled evidence at all for the addiction and withdrawal protocols that represent one of the largest commercial applications.
- 09Long-term safety of repeated high-dose exposure, including the oncological question, over any timeframe.
Forms & Administration
Intravenous infusion is the dominant form. Sessions are typically run over several hours because infusion-rate side effects — chest pressure, flushing, nausea — are the practical constraint, and slowing the rate is the standard way to manage them. Clinics commonly advertise sessions in the hundreds of milligrams to over a gram, and often sell them in multi-day series. There is no published dose-ranging study at any dose, so these amounts derive from practice convention rather than from evidence. Subcutaneous and intramuscular NAD+ are also sold, both by clinics and by grey-market peptide vendors supplying lyophilised powder for self-reconstitution. No human pharmacokinetic study of either route has been published, which means the basic question of systemic availability is unanswered. The approved product in China is an intramuscular injection at 5 mg, reportedly dosed at 2 to 5 mg once daily as an adjunct in leukopenia and in coronary heart disease and myocarditis. Readers comparing that figure against a clinic drip should note it is roughly two orders of magnitude smaller, and that it is the only NAD+ injection dosing anywhere that a regulator has reviewed. Sublingual, intranasal and topical NAD+ products exist in the supplement market. None has published human pharmacokinetic data, and the permeability argument against them is stronger than for the injectable routes given the molecule's size and charge.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
No established dose. Clinic infusions are commonly advertised in the hundreds of milligrams to over a gram per session; the only approved injection anywhere is 5 mg
Frequency
Typically a single multi-hour infusion or a series over consecutive days, depending entirely on the clinic
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Protocol Notes
There is no evidence-based dose for intravenous NAD+, because no dose-ranging study has ever been published. What follows is descriptive, so readers can interpret what they are offered. The only published human infusion protocol is the 2019 pharmacokinetic pilot: 3 µmol per minute for six hours, which works out to roughly 700 mg of NAD+ in total. That study was designed to measure fate, not effect, and found no plasma change for the first two hours. Wellness practice has converged on larger single sessions, commonly advertised in the hundreds of milligrams to over a gram, frequently packaged as a course of consecutive daily infusions. Nothing in the literature supports those amounts, the intervals, or the course lengths. Infusion rate, not total dose, is the variable that determines tolerability: chest pressure, flushing and nausea scale with how fast the drip runs, which is the real reason sessions are long. The contrast with the Chinese approved product is the most useful calibration available. Coenzyme I for Injection is a 5 mg intramuscular product reportedly dosed at 2 to 5 mg daily. Whatever one makes of its approved indications, it is the only NAD+ injection dosing that a regulator has examined, and it is smaller than a wellness infusion by a factor of roughly a hundred or more. That gap is not evidence that the larger doses are harmful. It is evidence that they have never been studied.
NAD+ is not approved by the FDA for any indication and no dose has been established in any published trial. Intravenous administration should only ever occur under direct medical supervision. Self-injection of NAD+ obtained from unregulated vendors carries sterility, identity and purity risks on top of a wholly unstudied pharmacology.
Timeline of Effects
Onset
Subjective effects — warmth, chest pressure, a feeling of clarity or of unease — are commonly reported within minutes of starting an infusion, and they track infusion rate. It is worth being precise about what that demonstrates: it shows the infusion is doing something perceptible, not that cellular NAD+ has risen. The one study that looked found no plasma change at all during the first two hours, so whatever a patient feels early in a session is not a readout of the mechanism being sold.
Peak Effect
Unknown and unmeasured. No study has characterised a peak effect for any clinical endpoint, because no study has measured a clinical endpoint. In the published pharmacokinetic pilot, the first detectable changes in plasma metabolites appeared after two hours and urinary excretion of methylnicotinamide and NAD+ was elevated by six hours.
After Discontinuation
Not studied. The cell-biology evidence suggests the relevant question is not withdrawal but whether anything persists at all: cells exposed to prolonged extracellular NAD+ reset their intracellular levels back to baseline by downregulating the transporters that import NAD+ breakdown products. No human study has measured tissue NAD+ after an infusion course ends, or at any other time.
Monitoring & Measurement
Bloodwork & Labs
- •Whole-blood or dried-blood-spot NAD+, the measure used in the one registered comparative trial — note it reports a blood pool, not tissue levels
- •Complete blood count, relevant to the one approved indication (leukopenia) and as general safety monitoring
- •Comprehensive metabolic panel including liver and kidney function, as baseline safety for any repeated parenteral course
- •Homocysteine, if methyl-donor balance is a concern with repeated high nicotinamide loads
When to Test
Baseline before any course, and repeat testing only in the context of a specific clinical question. There is no validated monitoring schedule for NAD+ infusion because there is no validated protocol to monitor.
Interpretation & Notes
This panel is listed with an important caveat: no biomarker here has been shown to predict or reflect benefit from an NAD+ infusion, because no benefit has been demonstrated. Blood NAD+ in particular is easy to sell as a progress measure and hard to interpret. It reports the circulating and blood-cell pool rather than NAD+ inside muscle, brain or liver, which is where the proposed biology happens and where nobody has measured anything in humans after an infusion. A rise in a dried-blood-spot NAD+ number after a drip would not establish that the intervention worked; a flat number would not establish that it failed. Anyone being offered serial NAD+ testing as proof an infusion course is working should understand that the test is measuring a compartment the claim is not about.
Common Questions
Does IV NAD+ actually raise NAD+ inside my cells?
Nobody has demonstrated that it does, and the available evidence points the other way. The one published human study — a six-hour infusion at 3 µmol per minute, about 700 mg in total — found no rise in plasma NAD+ or any of its measured metabolites for the first two hours, and concluded that NAD+ was being rapidly and completely cleared from plasma, with a metabolite pattern consistent with cleavage by NAD+ glycohydrolase and pyrophosphatase. Separately, a 2021 study in the Journal of Biological Chemistry found that when cells are exposed to extracellular NAD+ for a prolonged period, intracellular NAD+ rises and then resets to baseline, because the cells suppress CD73, the NMN transporter SLC12A8 and nicotinamide riboside kinase in a sirtuin-1-dependent way. No human study has measured intracellular NAD+ in tissue after an infusion at all, so the honest answer is that the central claim of the whole category is untested in humans and the indirect evidence is unfavourable.
Is IV NAD+ FDA-approved?
No. There is no FDA-approved NAD+ injection or infusion for any indication. What NAD+ does have is a specific and often-misrepresented compounding status: on the FDA's list of bulk drug substances nominated for use in 503A compounding, updated 14 May 2026, Nicotinamide Adenine Dinucleotide (NAD) and Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH) both sit in Category 1 — substances under evaluation, for which FDA does not currently intend to take enforcement action against compounding pending its review. A specific salt form, Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate, is in Category 3, meaning it was nominated without adequate support. Category 1 is a meaningfully better position than the one BPC-157 and TB-500 are in, and it is why compounding pharmacies can supply NAD+ while the agency deliberates. It is not an approval, not a finding of efficacy, and not a finding of safety.
Is NAD+ injection approved anywhere in the world?
Yes, in China, and the details are more interesting than the headline. Coenzyme I for Injection (注射用辅酶I) holds Chinese drug approval number 国药准字H41024721, held by Kaifeng Kangnuo Pharmaceutical, listed as a chemical drug at a 5 mg strength with an approval date of 15 July 2020 on the registry record — whether that is the original approval or a renewal is not clear from the record itself. The approved indications are adjunctive: leukopenia, and coronary heart disease and myocarditis. Reported label dosing is 2 to 5 mg intramuscularly once daily. Set that against what Western wellness clinics infuse — commonly advertised in the hundreds of milligrams to well over a gram per session — and the approved product is roughly two orders of magnitude smaller. A Chinese approval at 5 mg is not regulatory cover for a 1,000 mg drip.
Is it better than taking NMN or NR?
There is no evidence that it is, and there is a registered trial that was built to find out. NCT06382688 randomised 53 participants to intravenous NAD+, intravenous nicotinamide riboside, oral nicotinamide riboside or saline, with total NAD measured by dried blood spot alongside blood pressure and heart rate. It completed its primary collection in March 2024 — and no results have been posted, and its registry status is listed as unknown, with the last update in April 2024. Until that reads out, the comparison rests on a single infusion pharmacokinetic pilot on one side and dozens of randomised precursor trials showing reliable blood NAD+ increases on the other. On published evidence, oral precursors are the better-supported option, which is close to the opposite of how the two are usually marketed.
Does NAD+ help with addiction or withdrawal?
No study supports this. A PubMed search for intravenous NAD+ in addiction or withdrawal returns no results, and no randomised trial is registered. The practice traces to mid-twentieth-century work with niacinamide in alcoholism and to a body of clinic marketing rather than to controlled evidence. This matters more than the other unproven uses because of who is being sold it: people in withdrawal are medically fragile, sometimes at risk of seizures or delirium tremens, and an expensive multi-day infusion protocol with no evidence base can displace treatments that do have one.
What does an NAD+ infusion feel like, and why is it given so slowly?
Infusion-rate side effects are the defining practical feature of IV NAD+: chest pressure or tightness, flushing, nausea, abdominal cramping and a general sense of unease that tracks directly with how fast the drip runs. Slowing the rate reduces them, which is why sessions are often scheduled over several hours rather than minutes. These reactions are consistently described in clinic practice but have not been systematically characterised in any published trial, so their frequency, mechanism and relationship to dose are not formally established.
Is subcutaneous NAD+ from a peptide vendor the same thing?
It is the same molecule and a different risk profile. Subcutaneous and intramuscular NAD+ have appeared alongside research peptides from grey-market vendors, typically as a lyophilised powder for self-reconstitution. There is no published pharmacokinetic study of NAD+ by either route in humans, so the question of whether subcutaneous dosing delivers anything systemically useful is entirely open. The additional hazard is the ordinary one for self-injected unregulated product: sterility, endotoxin content, identity and purity are unverified, and injection is the route with the least margin for a contaminated preparation.
Who NAD+ (IV and Injectable) Is NOT For
- •Pregnancy and breastfeeding, where no data of any kind exist
- •Active or recent malignancy, where the theoretical concern about supporting the metabolic demands of rapidly dividing cells applies and has never been studied for the intravenous route
- •Anyone being offered NAD+ infusion as a treatment for substance withdrawal in place of evidence-based medical management
- •Known hypersensitivity to any component of a compounded preparation
- •Children and adolescents, in whom it has never been studied
- •Caution in anyone with cardiac disease given the consistent reports of chest pressure during infusion, which has never been formally characterised and whose mechanism is unknown
Drug & Supplement Interactions
No interaction study of intravenous NAD+ has been published, and the following is reasoning from the biochemistry rather than measured data. The interaction with the most theoretical weight concerns methyl-group balance. NAD+ breakdown yields nicotinamide, which is cleared partly by methylation to methylnicotinamide using S-adenosylmethionine as the methyl donor — and the 2019 infusion study found exactly this, with urinary methylnicotinamide rising while urinary nicotinamide did not. A large nicotinamide load therefore draws on the same methyl pool used by other methylation-dependent processes. Whether this is clinically meaningful in a well-nourished person is debated and unresolved, and it is the same question raised by high-dose oral precursors. Theoretical interactions with cancer therapy follow from the oncological caution above: agents whose mechanism involves DNA damage, and PARP inhibitors in particular, operate in a pathway that consumes NAD+, so the direction of any interaction is not obvious and has not been tested. This is a reason for oncological supervision, not a documented interaction. For athletes and anyone subject to anti-doping rules, the relevant constraint is not pharmacological but procedural: WADA prohibits intravenous infusions and injections of more than 100 mL per 12-hour period under section M2, independent of the substance infused. A typical NAD+ drip exceeds that volume. No clinically significant interactions have been reported with common chronic medications — statins, antihypertensives, antidepressants — but the absence of reports reflects the absence of study rather than evidence of safety.
Safety Profile
Common Side Effects
Cautions
- • No published trial has systematically collected adverse events for intravenous NAD+, so the side-effect profile above comes from clinical practice reports rather than from structured safety data
- • Any intravenous therapy carries line-associated risks — infection, phlebitis, infiltration — that are independent of the drug being infused
- • Compounded sterile injectables depend entirely on the compounding pharmacy's quality systems; NAD+ sits in FDA 503A Category 1, which permits compounding pending review but is not a quality guarantee
- • The doses used in wellness practice exceed the only internationally approved NAD+ injection strength by roughly two orders of magnitude, with no dose-ranging study at any dose
- • Theoretical oncological caution applies as it does to oral precursors: raising NAD+ availability could in principle support the metabolic demands of rapidly dividing cells. This has not been demonstrated in humans and has not been studied for the intravenous route at all
What We Don't Know
Almost everything that would matter clinically. Whether infused NAD+ raises NAD+ inside any human tissue has never been measured. Whether it produces any effect a patient would notice has never been tested against placebo. There is no dose-response study, no comparison of infusion rates, no characterisation of subcutaneous or intramuscular pharmacokinetics, and no long-term safety follow-up. The single published human pharmacokinetic study enrolled a small cohort for one six-hour session and was explicitly framed by its authors as a pilot. A category this widely sold has an evidence base that would be thin for a compound nobody had heard of.
Legal Status
United States
Not FDA-approved for any indication, in any form or route. NAD+ is available in the United States through compounding, and its specific status matters: on FDA's list of bulk drug substances nominated for 503A compounding, updated 14 May 2026, Nicotinamide Adenine Dinucleotide (NAD) and Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH) appear in Category 1 — under evaluation — while Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate appears in Category 3, nominated without adequate support. Category 1 means FDA has not completed its review and does not currently intend to act against compounding with the substance; it is not an approval and implies no finding on safety or efficacy. NAD+ is not among the six substances in Category 2, and it is not covered by the HHS peptide enforcement-discretion policy of 28 October 2026, which applies to six named peptides and does not include it. Oral NAD+ and NADH are separately sold as dietary supplements.
International
Approved in China and nowhere else that could be verified. Coenzyme I for Injection (注射用辅酶I) holds Chinese approval number 国药准字H41024721, held by Kaifeng Kangnuo Pharmaceutical, listed as a chemical drug at 5 mg with a registry approval date of 15 July 2020, indicated as an adjunct in leukopenia and in coronary heart disease and myocarditis. No marketing authorisation for injectable NAD+ was found in the EU, UK, Canada, Australia or Japan. Clinics in those jurisdictions that offer NAD+ infusions are generally operating through compounding or wellness-service pathways rather than with an approved medicine.
Sports & Competition
Not named anywhere on the WADA 2027 Prohibited List — not in S2, which covers peptide hormones and growth factors, and not in any other section. Whether the catch-all S0 category applies is genuinely arguable rather than settled. S0 captures any pharmacological substance not addressed by a later section and with no current approval by any governmental regulatory health authority for human therapeutic use; the Chinese approval of Coenzyme I for Injection is exactly the kind of approval that clause turns on. The same reasoning applies to noopept and its Russian registration. Athletes should treat the position as unresolved and seek a ruling rather than assume either answer, and should note separately that intravenous infusions above 100 mL per 12 hours are prohibited under M2 regardless of what is in the bag.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
IV NAD+ bypasses digestion, so it raises cellular NAD+ far better than oral NMN or NR.
Reality
Bypassing the gut is not the obstacle; the cell membrane is. Extracellular NAD+ meets CD38, pyrophosphatases and CD73 on the cell surface, which cleave it into precursors before uptake, and the salvage transporters import those precursors rather than the intact dinucleotide. The only published human infusion study found no plasma NAD+ increase for two hours and a metabolite profile its authors described as consistent with glycohydrolase and pyrophosphatase activity. Functionally, an NAD+ infusion may be a slow, expensive precursor infusion — and the oral precursors have dozens of randomised trials showing they reliably raise blood NAD+, which infused NAD+ does not.
Myth
You can feel it working during the infusion.
Reality
People do feel something, and that sensation is real — chest pressure, flushing, warmth, nausea, sometimes a rush of alertness. What it is not is evidence of the proposed mechanism. These reactions scale with infusion rate rather than with total dose, appear within minutes, and occur during the same window in which the one published study found no measurable change in plasma NAD+ at all. A strong subjective response to an infusion is among the weakest forms of evidence that a therapy is doing what it claims.
Myth
NAD+ being on an FDA list means the FDA has cleared it.
Reality
The list is of substances nominated for compounding, and NAD+ sits in Category 1, which means under evaluation. FDA has reached no conclusion; it has simply said it does not currently intend to act against compounding with the substance while it reviews. That is a better position than Category 2 or 3, which is probably why it gets cited, but it is not approval, not a finding of efficacy, and not a finding of safety. Separately, Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate sits in Category 3 — nominated without adequate support.
Myth
NAD+ infusions are an established treatment for addiction.
Reality
There is no published randomised trial, no registered trial, and a PubMed search for intravenous NAD+ in addiction or withdrawal returns nothing. The practice descends from mid-century orthomolecular work with high-dose niacinamide, not from controlled evidence, and has been sold for decades without anyone running the study. The population matters here: withdrawal can be medically dangerous, and an unevidenced multi-day infusion course can displace treatment that works.
Myth
If it is approved as a drug in China, the doses used in clinics must be safe.
Reality
The Chinese approval makes the opposite point. Coenzyme I for Injection is approved at a 5 mg strength, reportedly dosed at 2 to 5 mg intramuscularly once daily, as an adjunct in leukopenia and in coronary heart disease and myocarditis. Wellness infusions run from hundreds of milligrams to over a gram — roughly a hundredfold higher or more, by a different route, for entirely different indications. An approval at one dose says nothing about a dose two orders of magnitude larger, and no regulator has examined the larger one.
Published Research
10 studiesThe CD38 glycohydrolase and the NAD sink: implications for pathological conditions
SIRT1-dependent restoration of NAD+ homeostasis after increased extracellular NAD+ exposure
Shows that cells actively defend their NAD+ set point against external loading. Prolonged exposure to extracellular NAD+ produced an initial intracellular rise followed by a return to control levels — resetting — which radiolabelling attributed not to extrusion but to reduced uptake of NAD+ cleavage products, via suppressed expression of CD73, the NMN transporter SLC12A8 and nicotinamide riboside kinase. Silencing sirtuin 1 prevented both the transcriptional suppression and the resetting. The implication for any infusion strategy is that the ceiling may be set by the cell rather than by the dose.
NAD+ metabolism and its roles in cellular processes during ageing
A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+
The only published human pharmacokinetic study of an intravenous NAD+ infusion, and the single most important reference on this page. A six-hour infusion at 3 µmol per minute — roughly 700 mg in total — produced no change in plasma NAD+, nicotinamide, methylnicotinamide, ADP-ribose or NMN until after two hours. The authors' stated findings: NAD+ is rapidly and completely removed from the plasma for at least the first two hours; the metabolite profile is consistent with NAD+ glycohydrolase and pyrophosphatase activity; and urinary excretion products include NAD+ itself and methylnicotinamide but not nicotinamide. Explicitly framed as a pilot, and it remains unreplicated.
An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers
Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
NCT06382688 — The Effects of IV Administration of Niagen (Nicotinamide Riboside Chloride) As Compared to IV Administration of NAD+
The trial designed to answer the comparison question, and a cautionary record. Randomised, placebo-controlled, 53 participants actual, with arms for intravenous NAD+, intravenous nicotinamide riboside, oral nicotinamide riboside and saline, and outcomes of blood pressure, heart rate and total NAD by dried blood spot. Primary collection completed 8 March 2024. No results have been posted, the overall status is listed as unknown, and the last registry update was April 2024.
NCT06558253 — Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery After Cord Blood Transplantation
FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated 14 May 2026)
The primary source for this page's US regulatory claims. Nicotinamide Adenine Dinucleotide (NAD) and Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH) both appear in 503A Category 1, Bulk Drug Substances Under Evaluation. Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate appears separately in Category 3, Bulk Drug Substances Nominated Without Adequate Support. Category 2, which lists substances raising significant safety risks, contains six entries and NAD+ is not among them. Category 1 permits compounding pending FDA review; it is not an approval and carries no efficacy or safety finding.
Coenzyme I for Injection (注射用辅酶I) — Chinese drug approval 国药准字H41024721
Registry record for the only NAD+ injection known to hold a national marketing approval anywhere. Listed as a chemical drug, dosage form injection, strength 5 mg, marketing authorisation holder and manufacturer Kaifeng Kangnuo Pharmaceutical, approval date 15 July 2020. Chinese approval numbers are periodically renewed, so this date may reflect a renewal rather than first authorisation. Cited here for the existence, holder and strength of the approval; the 5 mg strength is the figure that matters, because it sits roughly two orders of magnitude below the doses used in wellness infusions.
NAD+ (IV and Injectable) Compared
Quick Facts
- Class
- Dinucleotide Coenzyme (Parenteral)
- Tier
- D
- Evidence
- Limited
- Safety
- Limited Data
- Updated
- Nov 2026
- Citations
- 10PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.